Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gains from Investment Securities (2021 - 2025)

Amylyx Pharmaceuticals has reported Gains from Investment Securities over the past 5 years, most recently at -$700000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at -$700000.0 for Q4 2025, down 138.31% from a year ago — trailing twelve months through Dec 2025 was $3.3 million (down 78.96% YoY), and the annual figure for FY2025 was $582315.0, down 92.47%.
  • Gains from Investment Securities for Q4 2025 was -$700000.0 at Amylyx Pharmaceuticals, down from $422239.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for AMLX hit a ceiling of $14.2 million in Q4 2022 and a floor of -$1.9 million in Q2 2021.
  • Median Gains from Investment Securities over the past 5 years was $2.0 million (2021), compared with a mean of $2.9 million.
  • Biggest five-year swings in Gains from Investment Securities: soared 15631.34% in 2023 and later tumbled 138.31% in 2025.
  • Amylyx Pharmaceuticals' Gains from Investment Securities stood at $1.7 million in 2021, then skyrocketed by 736.88% to $14.2 million in 2022, then crashed by 84.54% to $2.2 million in 2023, then dropped by 16.95% to $1.8 million in 2024, then tumbled by 138.31% to -$700000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were -$700000.0 (Q4 2025), $422239.0 (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.